SLGL
Sol-Gel Technologies Ltd.
Biotechnology
Market Cap$194M
5Y Perf.-7.9%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
SLGL vs VYNE vs DERM vs PRGO
Revenue, margins, valuation, and 5-year total return — side by side.
VYNE
VYNE Therapeutics Inc.
Biotechnology
Market Cap$29M
5Y Perf.-96.4%
DERM
Journey Medical Corporation
Drug Manufacturers - Specialty & Generic
Market Cap$102M
5Y Perf.-36.8%
PRGO
Perrigo Company plc
Drug Manufacturers - Specialty & Generic
Market Cap$1.61B
5Y Perf.-68.1%
SLGL vs VYNE vs DERM vs PRGO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SLGL | VYNE | DERM | PRGO |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $194M | $29M | $102M | $1.61B |
| Revenue (TTM) | $7M | $570K | $56M | $4.18B |
| Net Income (TTM) | $-15M | $-26M | $-9M | $-1.82B |
| Gross Margin | -153.5% | 99.1% | 67.5% | 34.2% |
| Operating Margin | -256.2% | -52.2% | -12.2% | -4.1% |
| Forward P/E | — | — | 69.0x | 5.6x |
| Total Debt | $991K | $0.00 | $26M | $3.97B |
| Cash & Equiv. | $11M | $24M | $20M | $532M |
SLGL vs VYNE vs DERM vs PRGO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SLGL
VYNE
DERM
PRGO
| Stock | Nov 21 | May 26 | Return |
|---|---|---|---|
| Sol-Gel Technologie… (SLGL) | 100 | 92.1 | -7.9% |
| VYNE Therapeutics I… (VYNE) | 100 | 3.6 | -96.4% |
| Journey Medical Cor… (DERM) | 100 | 63.2 | -36.8% |
| Perrigo Company plc (PRGO) | 100 | 31.9 | -68.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SLGL vs VYNE vs DERM vs PRGO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SLGL and DERM are tied at the top with 2 categories each — the right choice depends on your priorities. Journey Medical Corporation is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. PRGO and VYNE also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
SLGL
Sol-Gel Technologies Ltd.
The Growth Play
SLGL has the current edge in this matchup, primarily because of its strength in growth exposure.
- Rev growth 68.0%, EPS growth -478.9%, 3Y rev CAGR 70.9%
- 68.0% revenue growth vs DERM's -29.1%
- +8.0% vs PRGO's -51.2%
Best for: growth exposure
VYNE
VYNE Therapeutics Inc.
The Income Pick
VYNE is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.74
- Lower volatility, beta 0.74, current ratio 12.53x
- Beta 0.74, current ratio 12.53x
- Beta 0.74 vs DERM's 1.82
Best for: income & stability and sleep-well-at-night
DERM
Journey Medical Corporation
The Long-Run Compounder
DERM is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- -47.4% 10Y total return vs SLGL's -49.0%
- -15.5% margin vs VYNE's -46.5%
- -10.8% ROA vs VYNE's -63.3%, ROIC -56.8% vs -124.0%
Best for: long-term compounding
PRGO
Perrigo Company plc
The Value Play
PRGO is the clearest fit if your priority is value and dividends.
- Lower P/E (5.6x vs 69.0x)
- 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend
Best for: value and dividends
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SLGL | 68.0% revenue growth vs DERM's -29.1% |
| Value | PRGO | Lower P/E (5.6x vs 69.0x) |
| Quality / Margins | DERM | -15.5% margin vs VYNE's -46.5% |
| Stability / Safety | VYNE | Beta 0.74 vs DERM's 1.82 |
| Dividends | PRGO | 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend |
| Momentum (1Y) | SLGL | +8.0% vs PRGO's -51.2% |
| Efficiency (ROA) | DERM | -10.8% ROA vs VYNE's -63.3%, ROIC -56.8% vs -124.0% |
SLGL vs VYNE vs DERM vs PRGO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
FY 2024
FY 2025
SLGL vs VYNE vs DERM vs PRGO — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSLGLLAGGINGDERM
Who Leads Where
SLGL leads in 2 of 6 categories
PRGO leads 1 • VYNE leads 0 • DERM leads 0 • 2 tied
Explore the data ↓DERMJourney Medical Corpo…
0leads
VYNEVYNE Therapeutics Inc.
0leads
PRGOPerrigo Company plc
1leads
SLGLSol-Gel Technologies …
2leads
6 Total Categories
CATEGORYLEADERvs PRGOvs VYNEMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
PRGO4/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SLGL3/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
SLGL2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — SLGL and PRGO each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO is the larger business by revenue, generating $4.2B annually — 7330.5x VYNE's $570,000. DERM is the more profitable business, keeping -15.5% of every revenue dollar as net income compared to VYNE's -46.5%. On growth, SLGL holds the edge at +8.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SLGLSol-Gel Technolog… | VYNEVYNE Therapeutics… | DERMJourney Medical C… | PRGOPerrigo Company p… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $7M | $570,000 | $56M | $4.2B |
| EBITDAEarnings before interest/tax | -$16M | -$30M | -$3M | $58M |
| Net IncomeAfter-tax profit | -$15M | -$26M | -$9M | -$1.8B |
| Free Cash FlowCash after capex | $0 | -$33M | -$3M | $108M |
| Gross MarginGross profit ÷ Revenue | -153.5% | +99.1% | +67.5% | +34.2% |
| Operating MarginEBIT ÷ Revenue | -2.6% | -52.2% | -12.2% | -4.1% |
| Net MarginNet income ÷ Revenue | -2.3% | -46.5% | -15.5% | -43.5% |
| FCF MarginFCF ÷ Revenue | +1.4% | -58.1% | -4.8% | +2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +8.1% | +54.8% | +1.0% | -7.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +132.2% | +57.1% | +5.9% | -56.4% |
Evenly matched — SLGL and PRGO each lead in 2 of 6 comparable metrics.
Valuation Metrics
PRGO leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
| Metric | SLGLSol-Gel Technolog… | VYNEVYNE Therapeutics… | DERMJourney Medical C… | PRGOPerrigo Company p… |
|---|---|---|---|---|
| Market CapShares × price | $194M | $29M | $102M | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $184M | $5M | $108M | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | -31.61x | -1.09x | -6.94x | -1.14x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 68.97x | 5.56x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | 7.42x |
| Price / SalesMarket cap ÷ Revenue | 9.99x | 50.53x | 1.82x | 0.38x |
| Price / BookPrice ÷ Book value/share | 8.49x | 1.04x | 5.09x | 0.55x |
| Price / FCFMarket cap ÷ FCF | 704.54x | — | — | 11.12x |
PRGO leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
SLGL leads this category, winning 3 of 9 comparable metrics.
Profitability & Efficiency
SLGL delivers a -40.0% return on equity — every $100 of shareholder capital generates $-40 in annual profit, vs $-74 for VYNE. SLGL carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), SLGL scores 7/9 vs DERM's 2/9, reflecting strong financial health.
| Metric | SLGLSol-Gel Technolog… | VYNEVYNE Therapeutics… | DERMJourney Medical C… | PRGOPerrigo Company p… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -40.0% | -74.1% | -45.4% | -50.7% |
| ROA (TTM)Return on assets | -33.7% | -63.3% | -10.8% | -19.8% |
| ROICReturn on invested capital | -48.6% | -124.0% | -56.8% | +3.7% |
| ROCEReturn on capital employed | -28.0% | -74.5% | -34.2% | +4.3% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 2 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.04x | — | 1.28x | 1.35x |
| Net DebtTotal debt minus cash | -$10M | -$24M | $5M | $3.4B |
| Cash & Equiv.Liquid assets | $11M | $24M | $20M | $532M |
| Total DebtShort + long-term debt | $991,000 | $0 | $26M | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | — | — | -1.52x | -7.20x |
SLGL leads this category, winning 3 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — SLGL and DERM each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SLGL five years ago would be worth $7,289 today (with dividends reinvested), compared to $103 for VYNE. Over the past 12 months, SLGL leads with a +800.8% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors DERM at 44.7% vs VYNE's -57.3% — a key indicator of consistent wealth creation.
| Metric | SLGLSol-Gel Technolog… | VYNEVYNE Therapeutics… | DERMJourney Medical C… | PRGOPerrigo Company p… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +65.0% | +16.1% | -32.9% | -13.5% |
| 1-Year ReturnPast 12 months | +800.8% | -50.8% | -28.1% | -51.2% |
| 3-Year ReturnCumulative with dividends | +93.2% | -92.2% | +203.0% | -58.1% |
| 5-Year ReturnCumulative with dividends | -27.1% | -99.0% | -47.4% | -60.1% |
| 10-Year ReturnCumulative with dividends | -49.0% | -100.0% | -47.4% | -77.7% |
| CAGR (3Y)Annualised 3-year return | +24.5% | -57.3% | +44.7% | -25.2% |
Evenly matched — SLGL and DERM each lead in 3 of 6 comparable metrics.
Risk & Volatility
SLGL leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
SLGL is the less volatile stock with a -0.18 beta — it tends to amplify market swings less than DERM's 1.82 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SLGL currently trades 71.0% from its 52-week high vs VYNE's 34.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SLGLSol-Gel Technolog… | VYNEVYNE Therapeutics… | DERMJourney Medical C… | PRGOPerrigo Company p… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.18x | 0.74x | 1.82x | 1.18x |
| 52-Week HighHighest price in past year | $97.97 | $1.96 | $9.55 | $28.44 |
| 52-Week LowLowest price in past year | $6.57 | $0.28 | $4.31 | $9.23 |
| % of 52W HighCurrent price vs 52-week peak | +71.0% | +34.4% | +52.3% | +41.2% |
| RSI (14)Momentum oscillator 0–100 | 45.9 | 68.7 | 44.3 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 42K | 192K | 230K | 3.4M |
SLGL leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: SLGL as "Buy", DERM as "Buy", PRGO as "Hold". Consensus price targets imply 135.0% upside for DERM (target: $12) vs -28.1% for SLGL (target: $50). PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.
| Metric | SLGLSol-Gel Technolog… | VYNEVYNE Therapeutics… | DERMJourney Medical C… | PRGOPerrigo Company p… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Buy | Hold |
| Price TargetConsensus 12-month target | $50.00 | — | $11.75 | $20.00 |
| # AnalystsCovering analysts | 6 | — | 3 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +9.8% |
| Dividend StreakConsecutive years of raises | — | — | — | 10 |
| Dividend / ShareAnnual DPS | — | — | — | $1.15 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SLGL leads in 2 of 6 categories (Profitability & Efficiency, Risk & Volatility). PRGO leads in 1 (Valuation Metrics). 2 tied.
Best OverallSol-Gel Technologies Ltd. (SLGL)Leads 2 of 6 categories
Loading custom metrics...
SLGL vs VYNE vs DERM vs PRGO: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is SLGL or VYNE or DERM or PRGO a better buy right now?
For growth investors, Sol-Gel Technologies Ltd.
(SLGL) is the stronger pick with 68. 0% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). Analysts rate Sol-Gel Technologies Ltd. (SLGL) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SLGL or VYNE or DERM or PRGO?
Over the past 5 years, Sol-Gel Technologies Ltd.
(SLGL) delivered a total return of -27. 1%, compared to -99. 0% for VYNE Therapeutics Inc. (VYNE). Over 10 years, the gap is even starker: DERM returned -47. 4% versus VYNE's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SLGL or VYNE or DERM or PRGO?
By beta (market sensitivity over 5 years), Sol-Gel Technologies Ltd.
(SLGL) is the lower-risk stock at -0. 18β versus Journey Medical Corporation's 1. 82β — meaning DERM is approximately -1135% more volatile than SLGL relative to the S&P 500. On balance sheet safety, Sol-Gel Technologies Ltd. (SLGL) carries a lower debt/equity ratio of 4% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
04Which is growing faster — SLGL or VYNE or DERM or PRGO?
By revenue growth (latest reported year), Sol-Gel Technologies Ltd.
(SLGL) is pulling ahead at 68. 0% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: VYNE Therapeutics Inc. grew EPS 34. 0% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, SLGL leads at 70. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SLGL or VYNE or DERM or PRGO?
Journey Medical Corporation (DERM) is the more profitable company, earning -26.
1% net margin versus -46. 5% for VYNE Therapeutics Inc. — meaning it keeps -26. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -52. 2% for VYNE. At the gross margin level — before operating expenses — SLGL leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is SLGL or VYNE or DERM or PRGO more undervalued right now?
On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.
6x forward P/E versus 69. 0x for Journey Medical Corporation — 63. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DERM: 135. 0% to $11. 75.
07Which pays a better dividend — SLGL or VYNE or DERM or PRGO?
In this comparison, PRGO (9.
8% yield) pays a dividend. SLGL, VYNE, DERM do not pay a meaningful dividend and should not be held primarily for income.
08Is SLGL or VYNE or DERM or PRGO better for a retirement portfolio?
For long-horizon retirement investors, Sol-Gel Technologies Ltd.
(SLGL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 18)). Journey Medical Corporation (DERM) carries a higher beta of 1. 82 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SLGL: -49. 0%, DERM: -47. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between SLGL and VYNE and DERM and PRGO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SLGL is a small-cap high-growth stock; VYNE is a small-cap quality compounder stock; DERM is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while SLGL, VYNE, DERM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(SLGL: 814.6% · VYNE: 54.8%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.